• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc.

    10/25/24 9:46:32 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SWTX alert in real time by email
    SC 13G/A 1 ff4032041_13ga1-spring.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     


    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
     




    SpringWorks Therapeutics Inc.
    (Name of Issuer)

    Common Stock, par value $0.0001
    (Title of Class of Securities)

    85205L107
    (CUSIP Number)

    October 10, 2024
    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
    ____________
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    CUSIP No.: 85205L107
     
    13G
     Page 2 of 10 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Capital, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No.: 85205L107
     
    13G
     Page 2 of 10 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Asset Management Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     

     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No.: 85205L107
     
    13G
     Page 2 of 10 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Joe Lewis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No.: 85205L107
     
    13G
     Page 2 of 10 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Aaron I. Davis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    3,421,541
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    3,421,541
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,421,541
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    4.6%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     



    CUSIP No.: 85205L107
     
    13G
     Page 2 of 10 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Capital Management, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    3,421,541
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    3,421,541
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,421,541
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    4.6%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO; IA
     
     
     
     



    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the statement on Schedule 13G initially filed on September 19, 2022 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”) and Joe Lewis regarding the Common Stock of SpringWorks Therapeutics, Inc. On October 10, 2024, Boxer Capital entered into an investment management agreement (the “IMA”) with Boxer Capital Management LLC (“BCM”), a registered investment advisor controlled by Aaron I. Davis. Pursuant to the IMA, Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the securities held in Boxer Capital’s investment portfolio and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. To the extent applicable, the Original Filing, as hereby amended, is hereby adopted by BCM and Mr. Davis as their original filing on Schedule 13G regarding the Common Stock. The Original Filing, as amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 1. Capitalized terms used and not defined in this Amendment No. 1 have the meanings set forth in the Original Filing, as amended. Boxer Capital, Boxer Management, Mr. Lewis, Mr. Davis and BCM report herein that they have ceased to beneficially own more than 5% of the outstanding shares of Common Stock.
    Item 2(a): Name of Person Filing
    Item 2(a) is hereby amended and restated to read as follows:

    This Schedule 13G is jointly filed by Boxer Capital, Boxer Management, Mr. Lewis, Mr. Davis and BCM (collectively, the “Reporting Persons”).

    Boxer Management is the managing member and majority owner of Boxer Capital. Mr. Lewis is the sole indirect owner of and controls Boxer Management. BCM is a registered investment advisor, providing investment management services to Boxer Capital. Mr. Davis is the Managing Member of BCM and is a member of and has voting and dispositive power over securities beneficially held by BCM. With his immediate family, Mr. Davis indirectly owns the membership interests in BCM.

    Item 2(b): Address of Principal Business Office or, if None, Residence

    Item 2(b) is hereby amended and restated to read as follows:

    The principal business address of Boxer Capital, Mr. Davis and BCM is: 12860 El Camino Real, Suite 300, San Diego, CA 92130. The principal business address of Boxer Management and Mr. Lewis is: Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas.

    Item 2(c): Citizenship

    Item 2(c) is hereby amended and restated to read as follows:

    Boxer Capital and BCM are limited liability companies organized under the laws of Delaware. Boxer Management is a Bahamian international business company. Mr. Lewis is a citizen of the United Kingdom. Mr. Davis is a citizen of the United States of America.

    Item 4: Ownership

    Item 4 is hereby amended and restated to read as follows:


    (a)
    Amount beneficially owned:  BCM and Mr. Davis beneficially own 3,421,541 shares of Common Stock. The Reporting Persons beneficially own, in the aggregate, 3,421,541 shares of Common Stock.
    (b)
    Percent of class: All percentages of beneficial ownership set forth herein are based on 74,273,027 shares of Common Stock reported outstanding on August 1, 2024 in the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on August 7, 2024. The number of shares of Common Stock beneficially owned by the Reporting Persons in the aggregate represents 4.6% of the Issuer’s outstanding shares of Common Stock.
    (c)
    Number of shares as to which such person has:
    (i)
    sole power to vote or to direct the vote: None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.
    (ii)
    shared power to vote or to direct the vote: BCM and Mr. Davis have shared power to vote or to direct the vote of  3,421,541 shares of Common Stock.
    (iii)
    sole power to dispose or to direct the disposition of: None of the Reporting Persons has sole power to dispose or to direct the disposition of any shares of Common Stock.
    (iv)
    shared power to dispose or to direct the disposition of: BCM and Mr. Davis have shared power to dispose or to direct the disposition of 3,421,541 shares of Common Stock.
    Item 5: Ownership of Five Percent or Less of a Class
    With respect to the Reporting Persons:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
    Item 6: Ownership of More than Five Percent on Behalf of Another Person

    Item 6 is hereby amended and restated to read as follows:

    Other than as may result from indirect interests of investors in Boxer Capital, no persons other than the Reporting Persons have the right to receive or the power to direct the receipt of dividends, or proceeds of sale of the securities disclosed herein.

    Item 10: Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
    Exhibits
     
     
    2
     
    Joint Filing Agreement, dated October 25, 2024, among the Reporting Persons.




    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated:  October 25, 2024
     

     
    BOXER CAPITAL, LLC
     
     
     
     
     
    By:
     /s/ Aaron I. Davis
     
     
     
    Name:  
    Aaron I. Davis
     
     
    Title:
    Authorized Signatory
     
     
     
     
    BOXER ASSET MANAGEMENT INC.
     
     
     
     
     
    By:
     /s/ Paul Higgs
     
     
     
    Name:
    Paul Higgs
     
     
    Title:
    Director
     
     
     
     
    JOSEPH C. LEWIS
     
     
     
     
     
     /s/ Joseph C. Lewis
     
      
    Joseph C. Lewis, Individually
     
     
     
     
     
    MVA INVESTORS, LLC
     
         
     
    By:
     /s/ Aaron I. Davis  
       
    Name:
    Aaron I. Davis
       
    Title:
    Authorized Signatory
         
     
    AARON I. DAVIS 
     
         
     
     /s/ Aaron I. Davis
     
      
    Aaron I. Davis, Individually
     
     
     
    BOXER CAPITAL MANAGEMENT, LLC
     
         
     
    By:
     /s/ Aaron I. Davis  
       
    Name:
    Aaron I. Davis
       
    Title:
    Managing Member




    Get the next $SWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWTX

    DatePrice TargetRatingAnalyst
    11/20/2024$60.00Outperform
    Evercore ISI
    2/5/2024$75.00Buy
    Guggenheim
    12/1/2022$45.00Buy
    BofA Securities
    9/8/2021$97.00 → $105.00Overweight
    JP Morgan
    8/5/2021$136.00 → $137.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SWTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by SpringWorks Therapeutics Inc.

      10-Q - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      5/9/25 4:17:26 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by SpringWorks Therapeutics Inc.

      SCHEDULE 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      5/7/25 11:01:53 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.

      DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      4/28/25 4:02:03 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on SpringWorks Therapeutics with a new price target

      Evercore ISI initiated coverage of SpringWorks Therapeutics with a rating of Outperform and set a new price target of $60.00

      11/20/24 8:20:27 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on SpringWorks Therapeutics with a new price target

      Guggenheim initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $75.00

      2/5/24 8:04:18 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on SpringWorks Therapeutics with a new price target

      BofA Securities initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $45.00

      12/1/22 7:57:05 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc.

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      10/25/24 9:46:32 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/24 6:41:08 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/24 8:56:14 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

      – Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas – – Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in

      4/28/25 2:13:33 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

      Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $3.9 billion Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for the Healthcare business of Merck KGaA, Darmstadt, Germany SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas Planned acquisition will strengthen the presence of the Healthcare business of Merck KGaA, Darmstadt, Germany, i

      4/28/25 2:11:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

      STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025. About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases an

      4/27/25 10:35:13 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

      For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

      11/27/23 5:34:21 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

      Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

      11/27/23 5:34:04 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Financials

    Live finance-specific insights

    See more
    • SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

      – Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

      2/20/25 6:30:32 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

      STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas

      1/30/25 7:00:50 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      – Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – – $498 million in cash, cash equivalents and marketable securities as of September 30, 2024; expected to fund the Company through profitability, which is anticipated in the first

      11/12/24 6:30:21 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Edris Badreddin sold $1,084,592 worth of shares (20,000 units at $54.23), decreasing direct ownership by 11% to 169,712 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      3/5/25 6:33:49 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib covered exercise/tax liability with 30,756 shares and sold $2,657,656 worth of shares (49,000 units at $54.24), decreasing direct ownership by 8% to 954,869 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      3/5/25 6:32:29 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib sold $1,768,401 worth of shares (29,328 units at $60.30), decreasing direct ownership by 3% to 1,034,625 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/24/25 6:58:58 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Leadership Updates

    Live Leadership Updates

    See more
    • SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

      STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional," said Saqib Islam, Chief Executive Officer of SpringWorks. "His expertise

      7/29/24 6:30:11 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

      STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. "Tai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery

      9/11/23 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

      STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. ("AbbVie") until his retirement last year, brings over 30 years of experience in global commercial strategy and operations. "Carlos' success in building and leading global commercial organizations will be valuable as SpringWorks continues its planned transition into a commercial-stage compa

      7/15/22 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care